Targeting the Lysosomal Degradation of Rab22a‐NeoF1 Fusion Protein for Osteosarcoma Lung Metastasis

Cuiling Zeng,Li Zhong,Wenqiang Liu,Yu Zhang,Xinhao Yu,Xin Wang,Ruhua Zhang,Tiebang Kang,Dan Liao

DOI: https://doi.org/10.1002/advs.202205483

IF: 15.1

2022-12-20

Advanced Science

Abstract:In osteosarcoma cells, Rab22a‐NeoF1 fusion protein can be polyubiquitinated at lysine112 via the K63‐linked ubiquitin chains and then be recognized by autophagy receptor NDP52, leading to the lysosomal degradation of Rab22a‐NeoF1. This process is promoted by PINK1 kinase via phosphorylating Rab22a‐NeoF1 at serine120, and Sorafenib and Regorafenib can diminish osteosarcoma lung metastasis induced by Rab22a‐NeoF1 through upregulating PINK1. Rab22a‐NeoF fusion protein has recently been reported as a promising target for osteosarcoma lung metastasis. However, how this fusion protein is regulated in cells remains unknown. Here, using multiple screenings, it is reported that Rab22a‐NeoF1 fusion protein is degraded by an E3 ligase STUB1 via the autophagy receptor NDP52‐mediated lysosome pathway, which is facilitated by PINK1 kinase. Mechanistically, STUB1 catalyzes the K63‐linked ubiquitin chains on lysine112 of Rab22a‐NeoF1, which is responsible for the binding of Rab22a‐NeoF1 to NDP52, resulting in lysosomal degradation of Rab22a‐NeoF1. PINK1 is able to phosphorylate Rab22a‐NeoF1 at serine120, which promotes ubiquitination and degradation of Rab22a‐NeoF1. Consistently, by upregulating PINK1, Sorafenib and Regorafenib can inhibit osteosarcoma lung metastasis induced by Rab22a‐NeoF1. These findings reveal that the lysosomal degradation of Rab22a‐NeoF1 fusion protein is targetable for osteosarcoma lung metastasis, proposing that Sorafenib and Regorafenib may benefit cancer patients who are positive for the RAB22A‐NeoF1 fusion gene.

materials science, multidisciplinary,nanoscience & nanotechnology,chemistry